Neurogen Corporation Announces Webcast of Presentation At UBS Global Life Sciences Conference
PR Newswire, Tuesday, September 16, 2003 at 16:58
BRANFORD, Conn., Sep 16, 2003 /PRNewswire-FirstCall via COMTEX/ -- Neurogen Corporation (Nasdaq: NRGN), an innovative small molecule drug discovery and development company, announced today that its presentation at the UBS Global Life Sciences Conference Tuesday, September 23, 2003 will be webcast live from the Plaza Hotel in New York. The presentation at 3:00 p.m. ET may be accessed through the UBS website www.ibb.ubs.com, in the conferences section, or through a link in the investor relations section of Neurogen's website, www.neurogen.com. The presentation will be archived until October 25, 2003.
William H. Koster, PhD, President and CEO of Neurogen, will provide an overview of the Company's pipeline, including two Phase II trials for rheumatoid arthritis and for asthma now being conducted in Neurogen's inflammation program.
Neurogen Corporation targets new small molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical need, including inflammation, pain, insomnia, depression, and obesity. Neurogen has generated a portfolio of compelling new drug candidates through its Accelerated Intelligent Drug Discovery (AIDD(TM)) system, its expertise in cellular functional assays, and its depth in medicinal chemistry. Neurogen conducts its research and development independently and, when advantageous, collaborates with world-class pharmaceutical companies to obtain additional resources and to access complementary expertise. |
